Contralateral breast cancer a risk for women with dense tissue

Compared with breast-cancer patients who have nondense tissue, those with dense tissue are at significantly elevated risk of developing a tumor in the opposite breast.

That’s according to a study conducted at the University of Texas MD Anderson Cancer Center and published online Jan. 30 in Cancer.

Carlos Barcenas, MD, MSc, and colleagues reviewed the cases of 229 cancer patients who had developed contralateral breast cancer (CBC) and compared their records with those of 451 controls who did not develop CBC.

They categorized each patient’s mammographic breast density, assessed at the time of first breast-cancer diagnosis, as “nondense” or “dense” in accordance with the American College of Radiology’s characterizations for each.

They used multivariable conditional logistic regression models for statistical analysis.

Their key finding: After adjustment for potential prognostic risk factors for breast cancer, the odds of developing CBC proved significantly higher for patients with dense breasts (odds ratio, 1.80; 95 percent confidence interval, 1.22-2.64 [P<.01]) than for those with nondense breasts.

The team also observed that, among the cancer cases, 39.3 percent had nondense breast tissue and 60.7 percent had dense breast tissue. Among the controls, 48.3 percent had nondense breast tissue and 51.7 percent had dense breast tissue.

Patients who received chemotherapy or endocrine therapy were less likely to develop CBC, the authors report.

“In women with primary breast cancer, mammographic breast density appears to be a risk factor for the development of contralateral breast cancer,” the authors conclude. 

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.